EDSA - CIK 0001540159
The table below shows Edesa Biotech, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.32M | -$4.89M | -$6.64M | -$12.28M | -$13.66M | -$4.99M |
| Capital expenditure | - | - | $0.00 | $5.66K | $6.15K | $4.86K |
| Investing cash flow | - | - | $0.00 | -$5.66K | -$6.15K | $19.07K |
| Dividends paid | - | - | - | - | - | - |
Edesa Biotech, Inc. reported operating cash flow of -$7.32M for fiscal year 2025. That is down 49.7% from -$4.89M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$4.41M (FY 2015) to -$7.32M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $17.03M | $592.03K | $4.83M | $11.63M | $14.17M | $7.09M |